Sionna Therapeutics, Inc. (SION) AI Stock Analysis

• Market Cap: $1.63B
• Dividend Yield: N/A
• Average Volume (3M): 257.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.46
• Shares Outstanding: 44,628,788
• 10 Day Avg. Volume: 161,224
• 30 Day Avg. Volume: 257,638
• PEG Ratio: -0.58
• Price to Book (P/B): -6.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -20.89
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -6.43K
• Enterprise Value/Ebitda: -21.10
• 1Y Price Target: $47.80
• Price Target Upside: 30.82% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -2.26
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $44.00 ▲(20.42% Upside)
• Action: N/A Date: 01/04/26
• Date: Action: N/A 01/04/26

The score is primarily constrained by weak financial performance—no revenue, widening losses, rising cash burn, and deeply negative equity—implying elevated financing risk. Technicals are mixed but currently soft (below key short-term averages with weak momentum), while valuation is also pressured by ongoing unprofitability and lack of dividend support.

Positive Factors

Larger asset base

The sharp rise in reported assets provides tangible near-term resources to fund R&D and clinical programs without immediate commercial revenue. A larger asset base strengthens operational runway and supports program execution over the next several months, reducing short-term financing urgency.

Low absolute debt

Modest reported debt limits interest and covenant pressure, preserving financial flexibility for a development-stage biotech. Low leverage reduces the likelihood that servicing debt will crowd out R&D spending or force distressed financings during the next funding cycles.

Focused therapeutic pipeline

A clear, specialist focus on cystic fibrosis and CFTR-targeted therapeutics concentrates expertise and resources, enhancing development efficiency and partner appeal. This focused strategy supports disciplined program prioritization and makes the company a logical collaborator or acquisition target in the CF space.

Negative Factors

No revenue

Persistent absence of operating revenue means the business lacks commercial cash inflows and must rely on external financing to sustain operations. Over a multi-quarter horizon this elevates dilution and financing risk, and delays any shift toward self-sustaining cash generation.

Rising losses and cash burn

Widening net losses coupled with increasing operating cash outflows show accelerating cash consumption to advance R&D. This trend shortens runway and raises the probability of additional equity or debt raises within the 2–6 month horizon, increasing dilution or refinancing risk.

Deeply negative shareholders' equity

A materially negative and worsening equity position reflects accumulated deficits and weak capital buffer. Negative equity can constrain borrowing, complicate partner negotiations, and increase likelihood of dilutive financings or restructurings if losses persist over the coming quarters.

Sionna Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

How the Company Makes Money

Sionna Therapeutics, Inc. Financial Statement Overview

Summary

Development-stage profile with no revenue (2022–2024), widening net losses and rising cash burn, indicating continued reliance on external funding. Positives include a sharply higher 2024 asset base and modest absolute debt, but these are outweighed by deeply negative and worsening equity and accelerating operating/free cash outflows.

Income Statement

The company reports no revenue across 2022–2024, consistent with an early-stage biotech profile. Losses are widening over time (net loss of about $40.2M in 2022, $47.3M in 2023, and $61.7M in 2024), indicating rising operating spend without offsetting commercial or collaboration revenue. Profitability is therefore weak, though the trajectory can be typical for R&D-heavy development-stage businesses.

Balance Sheet

Assets increased sharply in 2024 (about $185.8M vs. $51.9M in 2023), which supports near-term operating capacity. However, stockholders’ equity is deeply negative and deteriorating (approximately -$69.9M in 2022 to -$163.7M in 2024), which is a notable balance-sheet risk signal. Total debt remains modest (about $9.7M in 2024), but the negative equity position limits financial flexibility and can increase reliance on external funding.

Cash Flow

Cash burn is substantial and rising, with operating cash flow at about -$36.1M (2022), -$43.7M (2023), and -$52.8M (2024), and free cash flow similarly negative (about -$52.8M in 2024). Free cash flow roughly tracks net losses (free cash flow to net income near ~1x), suggesting losses are largely cash-backed rather than purely accounting-driven. While reported free cash flow growth looks strong in 2024, it reflects a more negative base rather than improving cash generation, highlighting continued dependence on financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00
Gross Profit	-247.00K	-668.00K	0.00	0.00
EBITDA	-75.29M	-69.89M	-49.75M	-41.25M
Net Income	-70.68M	-61.69M	-47.26M	-40.24M
Balance Sheet
Total Assets	339.27M	185.75M	51.95M	87.37M
Cash, Cash Equivalents and Short-Term Investments	248.33M	147.54M	38.52M	82.61M
Total Debt	8.97M	9.75M	10.48M	0.00
Total Liabilities	17.60M	349.46M	166.83M	157.29M
Stockholders Equity	321.67M	-163.71M	-114.88M	-69.92M
Cash Flow
Free Cash Flow	-61.65M	-52.81M	-44.81M	-37.94M
Operating Cash Flow	-61.45M	-52.79M	-43.70M	-36.07M
Investing Cash Flow	-126.11M	-126.91M	27.35M	-29.26M
Financing Cash Flow	202.64M	178.97M	31.00K	110.86M

Sionna Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	61 Neutral	$2.08B	55.18	15.02%	―	1128.17%	―
VIR	59 Neutral	$1.27B	-2.87	-45.73%	―	-78.55%	7.74%
IMTX	56 Neutral	$1.39B	-9.46	-29.00%	―	-27.61%	-69.49%
AMLX	56 Neutral	$1.67B	-8.43	-56.52%	―	-100.34%	52.85%
TNGX	53 Neutral	$1.50B	-12.15	-51.65%	―	53.28%	21.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SION	47 Neutral	$1.63B	-22.86	-28.07%	―	―	―